Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis

Ying Li,Yan Ge,Fu You Liu,You Ming Peng,Lin Sun,Jun Li,Qiong Chen,Yan Sun,Kun Ye

DOI: https://doi.org/10.1007/s11010-011-1091-z

IF: 3.842

2011-01-01

Molecular and Cellular Biochemistry

Abstract:Progressive renal tubulointerstitial fibrosis is a common final pathway of nearly all forms of chronic kidney disease. Many efforts have been done to arrest or prevent renal tubulointerstitial fibrosis but with little progress. Nowadays, few therapeutic agents are available in clinical use. Norcantharidin (NCTD) is of great benefit in anticancer treatment, by inducing cell apoptosis, inhibiting cell proliferation, in addition, blocking tumor metastasis and angiogenesis in cancer, whereas little attention is given to its relationship with other diseases. Our recent studies demonstrated that NCTD was protective against renal tubulointerstitial fibrosis both in vivo and in vitro. The underlying mechanisms may include modulation of TGF-β1/Smad signal cascade, inhibition of protein serine/threonine phosphatases (PPP) as well as NF-κB. NCTD may be a promising therapeutic agent for renal tubulointerstitial fibrosis. In the present article, we will review the action of NCTD in renal tubulointerstitial fibrosis and discuss its possible mechanisms.